Anti-inflammatory Natural ProductsView this Special Issue
Research Article | Open Access
Minghua Lv, Feng Qiu, Tingting Li, Yuanjie Sun, Chunmei Zhang, Ping Zhu, Xiaokun Qi, Jun Wan, Kun Yang, Kui Zhang, "Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM", Mediators of Inflammation, vol. 2015, Article ID 460264, 11 pages, 2015. https://doi.org/10.1155/2015/460264
Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM
Epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein overexpressed in human epithelioma but with relatively low expression in normal epithelial tissues. To exploit this differential expression pattern for targeted cancer therapy, an EpCAM-targeted immunotoxin was developed and its antitumor activity was investigated in vitro. An immunotoxin (scFv2A9-PE or APE) was constructed by genetically fusing a truncated form (PE38KDEL) of Pseudomonas aeruginosa exotoxin with an anti-EpCAM single-chain variable fragment (scFv). ELISA and flow cytometry were performed to verify immunotoxin (scFv2A9-PE or APE) antigen-binding activity with EpCAM. Cytotoxicity was measured by MTT assay. Confocal microscopy was used to observe its cellular localization. The results of ELISA and flow cytometry revealed that the immunotoxin efficiently recognized recombinant and natural EpCAM. Its antigen-binding activity was relatively lower than 2A9. MTT assay confirmed potent reduction in EpCAM-positive HHCC (human hepatocellular carcinoma) cell viability (IC50 50 pM). Immunofluorescence revealed that the immunotoxin localized to endoplasmic reticulum 24 h later. In conclusion, we described the development of an EpCAM-targeted immunotoxin with potent activity against tumor cells, which may lay the foundation for future development of therapeutic antibody for the treatment of EpCAM-positive tumors.
The most ideal outcomes for tumor targeted therapy are improved patient survival and minimal adverse effects on normal tissues. Drugs that can specifically home to a cancer cell based on a surface receptor have helped to address that goal with the advent of monoclonal antibody therapy . Rituximab, directed against the CD20 antigen found on the surface of normal and malignant B cells, is the first monoclonal antibody approved by the US Food and Drug Administration for the treatment of B-cell non-Hodgkin’s lymphoma . Monoclonal antibodies have been developed and have been impressive, but they are limited by immunogenicity , thus, leading to the development of single-chain variable fragment (scFv) antibodies.
Researchers have designed and produced many scFvs since the 1980s. Recombinant scFvs are promising because they can target an effector molecule or a cell to a disease-related target structure [4, 5]. Immunotoxin, as one type of immunoconjugate, can be produced by genetically fusing scFv with toxin and this molecule can recognize target cells by scFv and kill them via its toxin. Many immunotoxins have undergone or are currently undergoing study in humans for leukemia treatment [6, 7]. Denileukin diftitox (Ontak) has been approved by the FDA for the treatment of cutaneous T-cell lymphoma in adults . Thus, immunotoxins are promising therapeutics for targeted cancer therapy.
Epithelial cell adhesion molecule (EpCAM), also known as CD326, is a type I membrane glycoprotein of approximately 40 kDa. It participates in many biological processes, such as cell adhesion, proliferation, and differentiation . EpCAM is frequently highly expressed on most solid tumors, including carcinomas of the breast, ovarian, lung, colon, and pancreatic cancer and in squamous cell carcinoma of the head and neck, suggesting its potential as a therapeutic target [10, 11].
EpCAM-targeted antibody therapy has been studied frequently since the 1980s. MAb17-1A, a low affinity monoclonal antibody against EpCAM, is successfully used in Germany for breast and colon carcinoma therapy [12, 13] and CD3/17-1A, a bispecific scFv, is demonstrated to have cytotoxicity to EpCAM-positive tumor cells in vitro . Finally, catumaxomab, a trifunctional anti-EpCAM/CD3 monoclonal antibody, has been approved in the European Union for the treatment of EpCAM-positive tumors in patients with malignant ascites . Due to limited applications and adverse effects of these antibodies, researchers wish to exploit more effective and EpCAM antibodies with greater potential to treat carcinomas. In the past 20 years, fully humanized and bispecific scFv fusion proteins have been studied in preclinical and clinical trials [16, 17] and EpCAM targeted immunotoxins have been confirmed to have antitumor activity in vitro . Simon made modification to an EpCAM-targeting fusion toxin by facile click PEGylation to increase its antitumor efficacy in vitro and in vivo . All these investigations have increased the promise of EpCAM as a target for cancer therapy.
We prepared seven EpCAM monoclonal antibodies, FMU-EpCAM-2A9, FMU-EpCAM-2D7, FMU-EpCAM-4B11, FMU-EpCAM-4F11, FMU-EpCAM-4E4, FMU-EpCAM-4A11, and FMU-EpCAM-4F6. FMU-EpCAM-2A9 and FMU-EPCAM-2D7 are also named FMU-Ep1 and FMU-Ep3, respectively. In previous work, we reported that some of these antibodies (FMU-Ep1 and FMU-Ep3) can be used for immunohistochemical staining to identify normal and malignant colon tissue . However, whether these are effective anticancer agents is uncertain. Thus, we report the construction, expression, and characterization of an immunotoxin, comprised of a single-chain variable fragment (scFv) of FMU-EpCAM-2A9 and a truncated form (PE38KDEL) of Pseudomonas aeruginosa exotoxin. The recombinant immunotoxin was successfully cloned and expressed and its antigen-binding ability and cytotoxicity were measured. This recombinant immunotoxin potently inhibited HHCC cell lines, which lays the foundation for further development of this agent as a possible cancer chemotherapeutic.
2. Materials and Methods
The recombinant plasmid PGEX-4T3-EpCAM and the monoclonal antibodies of EpCAM (FMU-EpCAM-2A9 and FMU-EpCAM-2D7) are all prepared in our lab. Fetal bovine serum and mRNA isolation kit are purchased from Gibco. FITC conjugated goat anti-mouse IgG is bought from Biolegend. Mouse anti-GST antibody, protein ultrafiltration centrifugal tube, and PVDF membrane are from Millipore. The primers used were synthesized by Shanghai Sangon Biotech Company. The sequences of the primers were listed in Table 1.
|B and F were degenerate primers; the degenerate base codes are as follows: s:c/g; m:a/c; r:a/g; w:a/t; k:g/t.|
Escherichia coli DH5α and BL21 were used for cloning of the pMD-T18-2A9-VH (or -VL) plasmid and pGEX-4T1-scFv plasmid, respectively. E. coli M15 was used to express the extracellular domain of EpCAM (pQE30-EpCAM).
2.3. Cell Lines and Cultures
The hepatocellular carcinoma cell lines (HHCC and SMMC-7721), breast cancer cell line (SKBR3), and colon cancer cells (Colo205 and SW480) are all from ATCC. They were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (100 units/mL penicillin and 100 μg/mL streptomycin) at 37°C and 5% CO2 in a humidified incubator.
2.4. Cloning Light and Heavy Chain Variable Region of FMU-EpCAM-2A9 (FMU-Ep1)
Hybridoma cells were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum. Cells were collected in the logarithmic phase and total RNA was extracted with Trizol according to the manufacturer’s instructions. The sequences encoding the light and heavy chain variable regions (VL and VH) of 2A9 were amplified by RT-PCR. The VH sequence was amplified using primers A and B, while the VL sequence was amplified with primers C and D. After purification, PCR products were cloned into a pMD-T18 vector and transformed into E. coli DH5α. The positive colony (pMD-T18-2A9-VH or pMD-T18-2A9-VL) was identified by colony PCR and restriction enzyme analysis.
2.5. Construction of the pGEX-4T1-scFv2A9-PE Expression Vector
The sequence encoding the 2A9-VH and 2A9-VL was amplified by PCR from plasmids pMD-T18-2A9-VH and pMD-T18-2A9-VL, respectively, and inserted into the pGEX-4T1 expression vector in two steps. A special linker was added to the N terminal of VL by forward primer. The peptide sequence of the linker was GGGGSGGGGSGGGGS. The 2A9-VH sequence was amplified by primers E and F, whereas the 2A9-VL sequence was amplified using primers G and H. After gel purification, the amplified VH products were digested, purified, and ligated between the BamH I and Sal I sites of plasmid vector pGEX-4T1. After identification of the pGEX-4T1-VH plasmid, the amplified VL products were ligated between the Sal I and EcoR I sites of plasmid vector pGEX-4T1-VH. The pGEX-4T1-VH-VL (pGEX-4T1-scFv2A9) vector was confirmed by restriction enzyme digestion and DNA sequencing. The sequence encoding a truncated form of Pseudomonas exotoxin (PE38KDEL) was amplified by PCR, and the template was kindly supplied by Professor Boquan Jin of the Fourth Military Medical University and cloned as an ~1,200 bp EcoR I-Xhol I fragment downstream of the scFv2A9 sequence present in the pGEX-4T1-based scFv2A9 expression vector. The primers used were I and J. The expression vector pGEX-4T1-scFv2A9-PE was identified by restriction enzyme digestion and DNA sequencing.
2.6. Protein Expression and Purification of the Immunotoxin against EpCAM
The pGEX-4T1-scFv2A9-PE plasmid was expressed in BL21 E. coli cells. Bacterial cultures were incubated at 37°C in LB growth medium containing 100 ng/mL ampicillin and grown until an early log phase (A600 nm = 0.6–0.8). Protein expression was induced for 7 h at 30°C by the addition of IPTG (final concentration 500 nM). Bacteria were harvested by centrifugation at 12,000 rpm for 20 min at 4°C. For purification, the pellet obtained from a 100 mL culture was resuspended in 10 mL 0.15 M PBS and pulse-sonicated for 30 × 1 min (1 s working and 1 s resting for a 1 min pulse and then cooled on ice for 1 min). The soluble and insoluble fractions were separated by centrifugation at 12,000 rpm for 20 min at 4°C. Then the soluble fraction was purified by using the Glutathione Resin GST Fusion Protein Purification Kit according to the manufacturer’s instructions (Genscript cat. number L00206). The purified immunotoxin was labeled by biotin according to the manufacturer’s instruction (Roche, Biotin Protein Labeling Kit).
2.7. Western Blotting Detection of the Immunotoxin against EpCAM
Purified protein samples were analyzed by electrophoresis on 10% SDS-PAGE under denaturing conditions and transferred to PVDF membrane. Western blot analysis was conducted using a mouse anti-GST antibody (the scFv was coexpressed with a GST tag) as the primary antibody (Millipore, 1 : 3000) and a horseradish peroxidase- (HRP-) labeled rabbit anti-mouse IgG as the secondary antibody, in accordance with the manufacturer’s protocols.
2.8. Construction of the pQE30-EpCAM Plasmid
The sequence encoding the extracellular domain of EpCAM was amplified by PCR from plasmid pGEX-4T-3-EpCAM and cloned as a 750 bp Kpn I - Hind III fragment to the plasmid pQE30. The primers used were K and L.
2.9. Prokaryotic Expression of pQE30-EpCAM
The pQE30-EpCAM plasmid was used to express the extracellular domain of EpCAM in M15 E. coli. Cells were grown at 37°C in a shaking incubator (220 rpm) until the culture reached an OD600 of 0.6–0.8. Protein expression was induced for 7 h at 30°C by adding IPTG (Sigma) at a final concentration of 500 nM. The harvested pellet was ultrasonicated and analyzed via SDS-PAGE Coomassie Blue staining and Western blot. The protein from the supernatant was purified with a Nickel-affinity chromatography column, in accordance with the manufacturer’s instruction (GE).
2.10. ELISA Detection of the Binding Ability of the Immunotoxin to EpCAM
The binding ability of the immunotoxin to EpCAM was detected by ELISA. Briefly, a 96-well plate was coated with 100 μL 5 μg/mL EpCAM-HIS recombinant protein overnight at 4°C in PBS. After incubation and washing, 100 μL 2A9 or immunotoxin was added to the wells at different concentrations (20, 2, 0.2, 0.02, and 0.002 μg/mL) and incubated for 1 h at 37°C. A mouse anti-GST primary antibody (1 : 500) and a HRP-labeled rabbit anti-mouse secondary antibody (1 : 2,500) were used to detect 2A9 or immunotoxin; the tetramethylbenzidine (TMB) was used to develop the ELISA results. All experiments were repeated three times.
2.11. Flow Cytometry Analysis
Colo205 and HHCC cells at 5 × 106 cells/mL were incubated with biotin labeled immunotoxin (20 μg/mL) or antibodies against EpCAM (20 μg/mL) for 40 minutes at 4°C. The cells were washed with PBS and then incubated with the FITC labeled avidin or antibodies for 30 minutes at 4°C. The fluorescence was examined by flow cytometry analysis using a FACScan flow cytometer (BD).
2.12. In Vitro Cytotoxicity Assay
Cytotoxic activity of the immunotoxin was measured with a standard MTT assay. Briefly, 4,000 HHCC cells were seeded in 96-well microplates in a total volume of 200 μL of culture medium/well. Immunotoxin (2–32.5 M) was added and cells were incubated for 72 h under standard cell culture conditions. Then, 20 μL of 5 mg/mL MTT solution was added to each well, and plates were incubated for 4 h at 37°C. Cell lysis and formazan solubilization were achieved by the addition of 150 μL DMSO, and released formazan crystals were allowed to dissolve 10 min at 37°C. Absorption was quantified at 490 nm using a microplate reader. All experiments were measured in triplicate.
Intracellular localization of the immunotoxin was observed by laser scanning confocal microscopy. Briefly, the HHCC cells were seeded in 24-well plates. After incubating for 8 h, biotin-labeled immunotoxin was added to the wells and incubated for different times. To localize the immunotoxin, cells were washed and fixed with 4% paraformaldehyde, and after blocking, cells were stained with primary antibody of the specific endoplasmic reticulum protein CRT (prepared in our laboratory). Fluorescence was measured by adding PE conjugated goat anti-mouse IgG and FITC-labeled avidin. Cell nuclei were stained with DAPI. After mounting, results were observed with laser scanning confocal microscopy.
2.14. Statistical Analysis
Differences between groups were determined using an unpaired two-tailed Student’s -test. Data analyses were performed using GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA). For all tests, a value less than 0.05 was considered significant.
3.1. Screening Parental Antibody against EpCAM
To screen the parental antibody of scFv, we compared the binding activity of two EpCAM mAbs (FMU-2A9 and FMU-2D7) with EpCAM on the surface of EpCAM-positive cells (Colo205 and HHCC) and EpCAM-negative cells (Sw480) by flow cytometry. Sw480 cells were similar to isotype control antibody (data not shown). The results of Colo205 and HHCC are depicted in Figure 1. 2A9 had relatively higher binding ability than 2D7 with the natural EpCAM molecule on these two cell surfaces. Thus, we selected 2A9 as the parental antibody to construct the scFv.
3.2. Construction, Expression, and Purification of the Immunotoxin
After three rounds of PCR, the plasmid pGEX4T1-scFv2A9-PE was constructed. Three separate products generated an ~2,000 bp immunotoxin (Figures 2(a) and 2(b)). The sequence of the immunotoxin (APE) was further confirmed by DNA sequencing (Figure 3). APE was expressed in BL21 E. coli, after sonication and purification, and samples were analyzed. SDS-PAGE and Western blot results (Figures 2(c) and 2(d)) indicated that the expressed GST-immunotoxin was ~95 kDa, which was consistent with the predicted molecule weight. Immunotoxin mainly interacted with inclusion bodies. To analyze immunotoxin activity, the GST tag was cut with thrombin and removed by purification, and the true molecule mass of the immunotoxin was 67 kDa (Figure 2(e)).
3.3. Construction, Expression, and Purification of the Extracellular Domain of EpCAM
To analyze the binding ability of the immunotoxin, we constructed and expressed the recombinant protein HIS-EpCAM. The plasmid pQE30-EpCAM was identified by restriction enzyme analysis (Figure 4(a)) and DNA sequencing. The expression of HIS-EpCAM was induced with 500 nM IPTG at 30°C for 7 h. After sonication and centrifugation of the bacteria, total protein, supernatants, and inclusion bodies were separated with 10% SDS-PAGE under reducing conditions. As shown in Figure 4(b), the expression strain produced the recombinant protein in both soluble and inclusion bodies form. Western blot (Figure 4(c)) confirmed a novel band at the predicted molecular weight of 32 kDa. After purification and identification, proteins were stored at −80°C for ELISA.
3.4. Binding Ability of Immunotoxin to EpCAM
Immunotoxin was successfully prepared, and the binding ability of the immunotoxin to EpCAM was tested by flow cytometry and ELISA. Briefly, prepared His-EpCAM or BSA was coated on 96-well plates, and the immunotoxin or 2A9 was added to detect recognition to EpCAM. Data showed (Figure 5(a)) that 2A9 had relatively higher binding ability with recombinant His-EpCAM (2 μg/mL) (unpaired -test, ). In fact, the binding activity of APE with His-EpCAM was weaker than 2A9 at other concentrations used (20, 0.2, 0.02, and 0.002 μg/mL, data not shown). Flow cytometry analysis (Figure 5(b)) demonstrated that the immunotoxin could efficiently recognize the EpCAM molecule on HHCC cells, although the binding ability was lower than 2A9. The mean fluorescent intensity of 2A9 was 25.02 ± 3.23, while the immunotoxin intensity was 10.03 ± 3.07.
3.5. Cytotoxicity Assay of Immunotoxin
The immunotoxin could bind to EpCAM in carcinoma cells, but whether it was cytotoxic to cancer cells requires more study. Cytotoxicity of the immunotoxin to EpCAM-positive (HHCC, Colo205, SMMC-7721, and SKBr3) and EpCAM-negative (Sw480) cells was tested by MTT assay. Data show (Figure 6(a)) that APE and PE both inhibited HHCC cell viability and had no other effect on other cells’ survival (data not shown). The IC50 of the immunotoxin to HHCC cells was 50 pM, and the control toxin exceeded 5,000 pM. This indicates that the immunotoxin can efficiently recognize certain cancer cells and has anticancer activity.
The mechanism of cytotoxicity was studied by immunofluorescence. After staining, the localization of the immunotoxin was observed by laser scanning confocal microscopy. Data show that (Figure 6(b)) after 6 h of incubation, the immunotoxin internalized to the HHCC cells and colocalized with CRT protein in the endoplasmic reticulum where it diffused uniformly in the endoplasmic reticulum after 24 h of incubation.
The challenging problem in cancer therapy is drug resistance and relapse. Thus, the development of novel drugs that target the specific antigen of carcinomas is greatly needed. EpCAM was reported to participate in the development and progression of diverse carcinomas as well as serve as a marker of prognosis , which triggered the study of EpCAM-target immunotherapy. EpCAM-specific antibodies were designed and used to treat many cancers in vitro and in vivo [22, 23]. Several EpCAM-target antibodies have been used in the clinic to treat malignant ascites and squamous cell carcinomas of the head and neck [24, 25], as well. These results suggest that EpCAM-targeted immunotoxin might be used to treat cancers.
In the current study, we designed, produced, and characterized a recombinant immunotoxin APE, comprised of an EpCAM scFv and PE38KDEL. We prepared seven EpCAM monoclonal antibodies, and they were used to identify CD326 at the 8th International Conference on HLDA (Human Leucocyte Differentiation Antigens) . The sequences encoding the light and heavy chain variable regions of four antibodies have been cloned and homology comparison and analysis of the nucleoside sequences of the four variable regions were performed using GenBank + EMBL + DDBJ + PDB databases. The DNASIS program was used to analyze the nucleotide sequence and deduce the amino acid sequence, which was “blasted” in nonredundant GenBank CDS translations + PDB + SwissProt + PIR + PRF protein databases. IMGT/V-QUEST was used to analyze the structure of variable region and determine the CDR region of the antibodies. Patents have been sought for these four sequences of variable regions (antibodies were FMU-EpCAM-2A9, FMU-EpCAM-2D7, FMU-EpCAM-4E4, and FMU-EpCAM-4F6). Our previous work indicated that all of the antibodies could be used to stain colon carcinoma tissues for immunohistochemistry , suggesting that they have the potential to become anticancer drugs. In this work, we used 2A9 and 2D7 as candidate antibodies to prepare scFv. FCM analysis showed that 2A9 had relatively higher binding ability to EpCAM on the surface of two EpCAM-positive cells. Similar results were observed in SMMC-7721 cells (data not shown). So we selected 2A9 as the parental antibody to construct scFv2A9. The constructed expression vector pGEX4T1-scFv2A9-PE was finally identified by DNA sequencing.
After purification and identification, we performed flow cytometry analysis and ELISA to measure immunotoxin activity. The original pGEX-4T3-EpCAM and the immunotoxin all have a GST tag and can be hardly distinguished by anti-GST antibody. To detect its antigen-binding activity, we expressed the recombinant protein HIS-EpCAM as an antigen. ELISA and flow cytometry analysis confirmed functionality, in which the APE can detect the EpCAM molecule as 2A9, though with relatively lower activity. This was consistent with flow cytometry results that 2A9 and APE can bind the natural EpCAM with different binding abilities. Characterization of the specificity and binding affinity of APE was also carried out with a competitive binding assay with the monoclonal 2A9 antibody and APE. To confirm that APE recognizes the same extracellular EpCAM epitope as the 2A9 mAb, APE was used to block the binding of the 2A9 monoclonal antibody. The results (data not shown) confirmed that APE could compete with 2A9 to certain extent, but incompletely. Previous studies demonstrated that high affinity anti-EpCAM antibodies could cause toxic effects (phase I trials) [27, 28], while antibodies with moderate affinity to EpCAM-positive cancers efficiently mediated both antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity [29–31]. We must characterize the anticancer activity of the immunotoxin.
The immunotoxin can recognize EpCAM, and whether it is cytotoxic to EpCAM-positive tumor cells must be confirmed. MTT assay demonstrated that APE induced a 50% reduction of viability (IC50) of HHCC cells at a concentration of 50 pM, compared to control PE (>5000 pM). These compounds did not affect other cancer cells. Previous work suggested that immunotoxin cytotoxicity was related to its cellular internalization . The immunotoxin has a C-terminal KDEL motif, which can localize it to the endoplasmic reticulum . We observed this localization in HHCC cells by immunofluorescence and this suggested that the immunotoxin might internalize to cells and transport to the endoplasmic reticulum to exert its function. This finding was consistent with a study on KDEL receptor . In addition, the internalization of the immunotoxin to Colo205 was also observed by immunofluorescence, and the immunotoxin was not detectable in cells after 24 h of incubation (data not shown).
The recombinant protein was expressed in E. coli cells as soluble form and as an inclusion body form (mainly). The soluble form of the protein maintained the natural structure and function and it could be used for function analysis . We purified the soluble protein from 4 L bacteria and 2 mg of purified APE was collected, a yield somewhat lower than previous reports [36, 37]. Because the inclusion body was the main form of the immunotoxin, in follow-up work, we will purify the protein from inclusion bodies .
Immunotoxin, comprised of scFv and toxin, has many advantages compared with other therapeutics, such as small molecular weight, fewer side effects, a simple preparation method, and low production cost. If the scFv used to construct an immunotoxin can be fully humanized, the therapeutic potential of the immunotoxin will be powerful.
In conclusion, we have successfully developed an immunotoxin made of a single-chain variable fragment (scFv), derived from EpCAM monoclonal antibody FMU-EpCAM-2A9 and PE38KDEL. Its antigen-binding ability and cytotoxicity have been confirmed in vitro. Future work will include optimization of protein production, further development and testing of immunotoxin-based targeted therapies in animal models, and modification of the immunotoxin to decrease immunogenicity and toxicity.
The research was approved by Ethical Standards Committee of Xijing Hospital.
Conflict of Interests
The authors have no conflict of interests.
Xiaokun Qi, Jun Wan, Kun Yang, and Kui Zhang contributed equally to this work. Minghua Lv, Feng Qiu, and Tingting Li are joint first authors.
This study was supported by Grants from the National Natural Science Foundation of China (no. 81401338), Natural Scientific Foundation of Beijing (Grant no. 7142148), and Capital Foundation for Medical Development and Research (Grant no. 2009-2054).
- J. G. Jurcic, D. A. Scheinberg, and A. N. Houghton, “Monoclonal antibody therapy of cancer.,” Cancer chemotherapy and biological response modifiers, vol. 15, pp. 152–175, 1994.
- G. A. Leget and M. S. Czuczman, “Use of rituximab, the new FDA-approved antibody,” Current Opinion in Oncology, vol. 10, no. 6, pp. 548–551, 1998.
- T. Yamaguchi and T. Takahashi, “Application of monoclonal antibody for cancer therapy,” Gan to Kagaku Ryoho, vol. 21, no. 2, pp. 157–162, 1994.
- B. E. Bejcek, D. Wang, E. Berven et al., “Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen,” Cancer Research, vol. 55, no. 11, pp. 2346–2351, 1995.
- D. Flieger, P. Kufer, I. Beier, T. Sauerbruch, and I. G. H. Schmidt-Wolf, “A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon α and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells,” Cancer Immunology Immunotherapy, vol. 49, no. 8, pp. 441–448, 2000.
- A. S. Wayne, R. J. Kreitman, H. W. Findley et al., “Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial,” Clinical Cancer Research, vol. 16, no. 6, pp. 1894–1903, 2010.
- R. J. Kreitman, M. S. Tallman, T. Robak et al., “Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia,” Journal of Clinical Oncology, vol. 30, no. 15, pp. 1822–1828, 2012.
- P. Piascik, “FDA approves fusion protein for treatment of lymphoma,” Journal of the American Pharmaceutical Association, vol. 39, no. 4, pp. 571–572, 1999.
- U. Schnell, V. Cirulli, and B. N. G. Giepmans, “EpCAM: structure and function in health and disease,” Biochimica et Biophysica Acta, vol. 1828, no. 8, pp. 1989–2001, 2013.
- P. A. Baeuerle and O. Gires, “EpCAM (CD326) finding its role in cancer,” British Journal of Cancer, vol. 96, no. 3, pp. 417–423, 2007.
- P. Went, M. Vasei, L. Bubendorf et al., “Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers,” British Journal of Cancer, vol. 94, no. 1, pp. 128–135, 2006.
- G. Riethmüller, E. Holz, G. Schlimok et al., “Monoclonal antibody therapy for resected Dukes' C colerectal cancer: seven-year outcome of a multicenter randomized trial,” Journal of Clinical Oncology, vol. 16, no. 5, pp. 1788–1794, 1998.
- E. M. Kirchner, R. Gerhards, and R. Voigtmann, “Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: Reduction of 17-1A-positive disseminated tumour cells,” Annals of Oncology, vol. 13, no. 7, pp. 1044–1048, 2002.
- M. Mack, G. Riethmuller, and P. Kufer, “A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 15, pp. 7021–7025, 1995.
- A. Burges, P. Wimberger, C. Kümper et al., “Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study,” Clinical Cancer Research, vol. 13, no. 13, pp. 3899–3905, 2007.
- D. A. Vallera, B. Zhang, M. K. Gleason et al., “Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells,” Cancer Biotherapy & Radiopharmaceuticals, vol. 28, no. 4, pp. 274–282, 2013.
- N. Shirasu, H. Yamada, H. Shibaguchi, and M. Kuroki, “Molecular characterization of a fully human chimeric T-cell antigen receptor for tumor-associated antigen EpCAM,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 853879, 7 pages, 2012.
- C. Di Paolo, J. Willuda, S. Kubetzko et al., “A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity,” Clinical Cancer Research, vol. 9, no. 7, pp. 2837–2848, 2003.
- M. Simon, N. Stefan, L. Borsig, A. Pleuckthun, and U. Zangemeister-Wittke, “Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEgylation,” Molecular Cancer Therapeutics, vol. 13, no. 2, pp. 375–385, 2014.
- X. Xie, C. Y. Wang, Y. X. Cao et al., “Expression pattern of epithelial cell adhesion molecule on normal and malignant colon tissues,” World Journal of Gastroenterology, vol. 11, no. 3, pp. 344–347, 2005.
- P. A. Baeuerle and O. Gires, “EpCAM (CD326) finding its role in cancer,” British Journal of Cancer, vol. 96, no. 3, pp. 417–423, 2007.
- D. Seimetz, H. Lindhofer, and C. Bokemeyer, “Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy,” Cancer Treatment Reviews, vol. 36, no. 6, pp. 458–467, 2010.
- K. Ogawa, S. Tanaka, S. Matsumura et al., “EpCAM-targeted therapy for human hepatocellular carcinoma,” Annals of Surgical Oncology, vol. 21, no. 4, pp. 1314–1322, 2014.
- C. Bokemeyer, “Catumaxomab trifunctional anti-EpCAM antibody used to treat malignant ascites,” Expert Opinion on Biological Therapy, vol. 10, no. 8, pp. 1259–1269, 2010.
- A. Premsukh, J. M. Lavoie, J. Cizeau, J. Entwistle, and G. C. MacDonald, “Development of a GMP Phase III purification process for VB4-845, an immunotoxin expressed in E. coli using high cell density fermentation,” Protein Expression and Purification, vol. 78, no. 1, pp. 27–37, 2011.
- H. Zola and B. Swart, “The human leucocyte differentiation antigens (HLDA) workshops: the evolving role of antibodies in research, diagnosis and therapy,” Cell Research, vol. 15, no. 9, pp. 691–694, 2005.
- J. Posey, M. Khazaeli, and M. Saleh, “Phase I trial testing multiple doses of humanized monoclonal antibody (Mab) 3622W94,” ASCO Annual Meeting, vol. 17, p. 436, 1998.
- J. S. de Bono, A. W. Tolcher, A. Forero et al., “ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas,” Clinical Cancer Research, vol. 10, no. 22, pp. 7555–7565, 2004.
- S. Naundorf, S. Preithner, P. Mayer et al., “In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment,” International Journal of Cancer, vol. 100, no. 1, pp. 101–110, 2002.
- W. Xiang, P. Wimberger, T. Dreier et al., “Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells,” Journal of Cancer Research and Clinical Oncology, vol. 129, no. 6, pp. 341–348, 2003.
- N. Prang, S. Preithner, K. Brischwein et al., “Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines,” British Journal of Cancer, vol. 92, no. 2, pp. 342–349, 2005.
- U. C. Wargalla and R. A. Reisfeld, “Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 13, pp. 5146–5150, 1989.
- K. Yamamoto, H. Hamada, H. Shinkai, Y. Kohno, H. Koseki, and T. Aoe, “The KDEL receptor modulates the endoplasmic reticulum stress response through mitogen-activated protein kinase signaling cascades,” Journal of Biological Chemistry, vol. 278, no. 36, pp. 34525–34532, 2003.
- M. Capitani and M. Sallese, “The KDEL receptor: new functions for an old protein,” FEBS Letters, vol. 583, no. 23, pp. 3863–3871, 2009.
- S. Song, J. Xue, K. Fan et al., “Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli,” Protein Expression and Purification, vol. 44, no. 1, pp. 52–57, 2005.
- L. M. Thomas, P. J. Huntington, L. J. Mead, D. L. Wingate, B. A. Rogerson, and A. M. Lew, “A soluble recombinant fusion protein of the transmembrane envelop protein of equine infectious anaemia virus for ELISA,” Veterinary Microbiology, vol. 31, no. 2-3, pp. 127–137, 1992.
- Y.-Q. Luo, L.-H. Wang, Q. Yi, and B.-H. Jiao, “Expression of soluble, biologically active recombinant human tumstatin in Escherichia coli,” Clinical and Experimental Medicine, vol. 8, no. 1, pp. 37–42, 2008.
- H. Wang, J. Dai, B. Li et al., “Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A,” Protein Expression and Purification, vol. 58, no. 1, pp. 140–147, 2008.
Copyright © 2015 Minghua Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.